Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Грибовидный микоз

Список литературы

  1. Korgavkar K., Xiong M., Weinstock M. Changing incidence trends of cutaneous Tcell lymphoma. JAMA Dermatol. 2013;149(11):1295–1299.
  2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneouslymphomas. Blood.2005;105(10):3768–3785.
  3. Keehn C.A., Belongie I.P., Shistik G. et al. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007;14(2):102–111.
  4. Cerroni L.Mycosis fungoides – clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37: 2–10.
  5. Willemze R.Mycosis fungoides variants – clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37:11–17.
  6. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Sosiety for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 1713-1722
  7. Horwitz S.M., Olsen E.A., Duvic M. et al. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008; 6 (4): 436–442.
  8. Delfau-Larue M.H., Laroche L., WechslerJ. et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood 2000; 96 (9): 2987–2992.
  9. Ponti R., Quaglino P., Novelli M. et al. T-cell receptor gamma gene rearrangement bymultiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneousT-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatorydisease: correlation with clinical, histological and immunophenotypical findings.Br J Dermatol. 2005;153(3):565–573.
  10. Kirsch I.R., Watanabe R., O’Malley J.T. et al. TCR sequencing facilitates diagnosisand identifies mature T cells as the cell of origin in CTCL. Sci Transl Med.2015;7(308):308ra158.
  11. Matos T.R., de Rie M.A., Teunissen M.B. Research techniques made simple: high-throughput sequencing of the T-cell receptor. J Invest Dermatol.2017;137(6):e131–e138.
  12. Scherer F., Kurtz D.M., Diehn M., Alizadeh A.A. High-throughput sequencing for noninvasivedisease detection in hematologic malignancies. Blood 2017;130(4):440–452.
  13. Jawed S.I., Myskowski P.L., HorwitzS. et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014; 70 (2): 205.e1–16.
  14. Rea B., Haun P., EmersonR.et al. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. J Clin Pathol 2018; 71 (9): 814–820.
  15. Ferner R.E. Adverse drug reactions in dermatology. Clin Exp Dermatol. 2015;40:105–109.
  16. MassimoFederico,MonicaBellei,LuigiMarcheseet. al. Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018 Jun; 181(6): 760–769
  17. Huang DY, Hu YF, Wei N, et. al. Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chin Med J (Engl).2019 Feb 5;132(3):294-301
  18. ELISEA. OLSEN. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic Therapy, Vol. 16, 2003, 311–321
  19. Jared M. Campbell,· Emma Bateman,· Matthew D. Stephenson1. Methotrexate‑induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta‑analyses. Cancer Chemother Pharmacol. DOI 10.1007/s00280-016-3043-5
  20. Mann, Johnson, Cohen et al. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. The Oncologist 2007;12:1247–1252
  21. H Miles Prince, Youn H Kim, Steven M Horwitz,et. al.Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. www.thelancet.com Vol 390 August 5, 2017; 555-566
  22. Onder Alpdogan, Saritha Kartan, William Johnson et al.Systemic therapy of cutaneous T-cell lymphoma (CTCL). ChinClinOncol2019;8(1):10
  23. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organizationclassification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  24. Guitart J., Kennedy J., Ronan S. et al. Histologiccriteria for the diagnosis of mycosis fungoides: proposal for a grading system tostandardize pathology reporting. J Cutan Pathol.2001;28(4):174–183.
  25. Raghavan S.S., KimJ. Histopathologic approach to epidermotropiclymphocytic infiltrates. Semin Cutan Med Surg 2018; 37:56–60.
  26. Charli-Joseph Y., Toussaint-Caire S., Lome-MaldonadoC. et al. Approach to dermal-based lymphoid infiltratesand proliferations. Semin Cutan Med Surg 2018; 37:61–74.
  27. Kempf W., Mitteldorf C. Pathologic diagnosis of cutaneous lymphomas. Dermatol Clin.2015; 33(4):655–681.
  28. Vandergriff T., Nezafati K.A., Susa J. et al. Defining early mycosis fungoides: validationof a diagnostic algorithm proposed by the International Society for CutaneousLymphomas. J Cutan Pathol. 2015;42(5):318–328.
  29. Pimpinelli N., Olsen E.A., Santucci M. et al. Defining early mycosis fungoides. J AmAcad Dermatol. 2005;53(6):1053–1063.
  30. Kash N., Massone C., Fink-Puches R., Cerroni L. Phenotypic variation in different lesions of mycosis fungoides biopsied within a short period of time from the same patient. Am J Dermatopathol. 2016;38(7):541–545.
  31. de Masson A., Battistella M., Vignon-Pennamen M.D. et al. Syringotropic mycosisfungoides: clinical and histologic features, response to treatment, and outcomein 19 patients. J Am Acad Dermatol. 2014;71(5):926–934.
  32. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. JAmAcadDermatol 2005;53(6):1053–63
  33. ZhangY, WangY, YuR, etal. Molecular markers of early-stage mycosis fungoides. JInvestDermatol 2012;132(6):1698–706
  34. Gerami P., Guitart J. The spectrum of histopathologic and immunohistochemicalfindings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31(9):1430–1438.
  35. Haghighi B., Smoller B.R., LeBoit P.E. et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000;13(5):502–510.
  36. Haththotuwa R, Zilinskiene L, Oliff J et. al. Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome. BrJDermatol.2017 Sep;177(3):877-878
  37. SalhanyKE, GreerJP, CousarJB, CollinsRD. Marrow involvementin cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases.Am J Clin Pathol 1989;92:747–54
  38. Kim E.J., Hess S., Richardson S.K. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest.2005;115(4):798–812.
  39. Zackheim H.S. Treatment of patch-stage mycosis fungoides with topical corticosteroids. DermatolTher. 2003;16(4):283–287
  40. Diederen P.V., van Weelden H., Sanders C.J. et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am AcadDermatol. 2003;48(2):215–219.
  41. Gathers R.C., Scherschun L., Malick F. et al.Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am AcadDermatol. 2002;47(2):191–197.
  42. Ponte P., Serrão V., Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J EurAcadDermatolVenereol. 2010;24(6):716–721.
  43. Кубанов А.А., Карамова А.Э., Знаменская Л.Ф., Воронцова А.А. Фототерапия грибовидного микоза. Онкогематология. 2019; 14 (4): 39–47.
  44. Querfeld C., Rosen S.T., Kuzel T.M. et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005; 141 (3): 305–311.
  45. Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma. DermatolTher. 2003; 16 (4): 311–321.
  46. Zackheim H.S., Kashani-Sabet M., McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003;49(5):873–878.
  47. Prince H.M., Whittaker S., Hoppe R.T. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009; 114: 4337–4353
  48. Duvic M., Talpur R., Ni X. et al. Phase 2 trial of oral vorinostat (suberoylanilidehydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109 (1): 31–39
  49. Olsen E.A., Kim Y.H., Kuzel T.M. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25 (21): 3109–3115.
  50. Duvic M., Olsen E.A., Breneman D. et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009; 9 (6): 412–416.
  51. Kim YH, Tavallaee M, Sundram U, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015;10(33(32)):3750-8.
  52. Prince HM, Kim YH, Horwitz SM, al. Brentuximab vedotin or physician"s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;5(390(10094)):555-566.
  53. Hoppe R.T. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003; 16 (4): 347–354
  54. Hymes K.B. Choices in the treatment of cutaneous T-cell lymphoma. Oncology (Williston Park). 2007; 21 (2 Suppl 1): 18–23.
  55. Н. В. Ильин, Е. Н. Николаева, Ю. Н. Виноградова и соавт. Применение лучевой терапии электронным пучком в лечении первичных лимфом кожи. Применение лучевой терапии электронным пучком в лечении первичных лимфом кожи. 2009; 1. С. – 27 -31
  56. Чистякова И.А., Самсонов В.А., Потекаев Н.С. и соавт. Лучевая терапия больных Т- клеточной лимфомой кожи. Вестн. Дерматол. Венерол. 2007; 6. С.- 34-36.
  57. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002–6.
  58. Franz Trautinger, Johanna Eder, Chalid Assaf, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment ofmycosis fungoides/Se ´zary syndrome e Update 2017. European Journal of Cancer 77 (2017) 57-74
  59. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000 Jul;18(13):2603-6
  60. Grozea PN, Jones SE, McKelvey EM., et al. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep. 1979 Apr;63(4):647-53
  61. Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang et al. Bortezomib in combination with CHOP as first-line treatmentfor patients with stage III/IV peripheral T-cell lymphomas: Amulticentre, single-arm, phase 2 trial. European Journal of Cancer, 48(17), 3223–3231
  62. Wu P.A., Kim Y.H., Lavori P.W. et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant. 2009;15(8):982–990
  63. Duarte R.F., Canals C., Onida F. et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–4499
  64. Serrano L., Martinez-Escala M.E., ZhouX.A., Guitart J. Pruritus in cutaneous T-cell lymphoma and its management.Dermatol Clin 2018; 36: 245–258] [Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564–568
  65. Weisshaar E., Szepietowski J.C., Dalgard F.J. et al. European S2k guideline on chronic pruritus. ActaDermVenereol. 2019; 99 (5): 469–506
  66. Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564–568
  67. Лезвинская Е.М., Вавилов А.М. Лимфопролиферативные опухоли кожи: руководство для врачей. – М.: Практическая медицина, 2010. – 366 с

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*